摘要
丙型肝炎(HC)为常见传染病,目前,全球已有超过1.7亿人群感染丙肝病毒,严重威胁人类健康。随着癌症发病率逐年增加,抗肿瘤治疗手段日益更新。接受抗肿瘤治疗后丙肝病毒的再激活成为不可忽视的问题。丙肝病毒再激活可能引起不同程度的肝功能损害,其对患者预后的影响、预防及治疗的最佳策略仍在研究中。
Hepatitis type C （HC） is a common infectious disease and there are more than 170 million people worldwide infected with hepatitis type C virus （HCV）, which is a serious threat to human health. With the increasing prevalence of cancer, the anti-cancer therapies are renewed day by day. HCV reactivation after anti- cancer therapy is an issue not to be neglected. It may cause hepatic injury in varying degrees, and its effect on the prognosis, prophylactic strategies and optimal treatments are still being researched.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2016年第12期1081-1084,共4页
Cancer Research on Prevention and Treatment
关键词
丙肝病毒
癌症
抗肿瘤治疗
再激活
肝损伤
Hepatitis C Virus
Cancer
Anti-cancer therapy
Reactivation
Hepatic injury
